CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation
Bioconjugate Chemistry · 2023
DOI: 10.1021/acs.bioconjchem.3c00391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Kyle D Apley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States. Hauptthemen laut MEDLINE: Insulin, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Pancreatic islet-reactive B lymphocytes promote Type 1 diabetes (T1D) by presenting an antigen to islet-destructive T cells. Teplizumab, an anti-CD3 monoclonal, delays T1D onset in patients at risk, but additional therapies are needed to prevent the disease entirely. Therefore, bifunctional molecules were designed to selectively inhibit T1D-promoting anti-insulin B cells by conjugating a ligand for the B cell inhibitory receptor CD22 (i.e., CD22L) to insulin, which permit these molecules to concomitantly bind to anti-insulin B cell receptors (BCRs) and CD22. Two prototypes were synthesized: 2:2 insulin-CD22L conjugate on a 4-arm PEG backbone, and 1:1 insulin-CD22L direct conjugate. Transgenic mice (125TgSD) expressing anti-insulin BCRs provided cells for in vitro testing. Cells were cultured with constructs for 3 days, then assessed by flow cytometry. Duplicate wells with anti-CD40 simulated T cell help. A 2-insulin 4-arm PEG control caused robust proliferation and activation-induced CD86 upregulation. Anti-CD40 further boosted these effects. This may indicate that BCR-cross-linking occurs when antigens are tethered by the PEG backbone as soluble insulin alone has no effect. Addition of CD22L via the 2:2 insulin-CD22L conjugate restored B cell properties to that of controls without an additional beneficial effect. In contrast, the 1:1 insulin-CD22L direct conjugate significantly reduced anti-insulin B cell proliferation in the presence of anti-CD40. CD22L alone had no effect, and the constructs did not affect the WT B cells. Thus, multivalent antigen constructs tend to activate anti-insulin B cells, while monomeric antigen-CD22L conjugates reduce B cell activation in response to simulated T cell help and reduce pathogenic B cell numbers without harming normal cells. Therefore, monomeric antigen-CD22L conjugates warrant futher study and may be promising candidates for preclinical trials to prevent T1D without inducing immunodeficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
- Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
- Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas 66045, United States.
- Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
- Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66045, United States.
- Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63130, United States.
ORCID-Profile: Kyle D Apley, Grant M Downes, Mark P Farrell, Cory J Berkland
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NCRR NIH HHS
- Division of Chemistry
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Division of Graduate Education
- National Institute of General Medical Sciences
Zitieren
APA
Apley, K. D., Griffith, A. S., Downes, G. M., Ross, P., Farrell, M. P., Kendall, P., & Berkland, C. J. (2023). CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00391
Vancouver
Apley KD, Griffith AS, Downes GM, Ross P, Farrell MP, Kendall P, et al. CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00391
BibTeX
@article{Apley2023,
author = {Apley, Kyle D and Griffith, Amber S and Downes, Grant M and Ross, Patrick and Farrell, Mark P and Kendall, Peggy and Berkland, Cory J},
title = {CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation},
journal = {Bioconjugate Chemistry},
year = {2023},
doi = {10.1021/acs.bioconjchem.3c00391}
}
EUVIMED